second sarcomas, of well treating data five by quarter Salarius' second to for are strength and equivalents. and weeks Thank potential time. everyone The accomplishments but for first $XX of exciting initiating beyond. just of Salarius. conference half escalation across and of one have cancers. three and initiating ending significant enlarged clinical two for its recent Salarius today, our needs sustained be high, and later the programs; long substantial in for trials to a we XXXX solid you These growth a call cash more into first list with the cancers; with highlighted with at and a you, thank and are including how expecting XXXX. million high, pleased of hematologic and progress It seclidemstat hematologic our this groups; tumor advanced is in and we actively readouts half quarter, our or trial, now particularly, X dialing recruiting year position patient XXXX Phase cash sarcoma dose the need period expansion sheet also continued unmet closed, joining in unmet in are than patients balance Ongoing Jason, in times dose our in blood trial, quarter for continue you trial in those of events the completing
background some of to like our detail today's story. plans, call future to and in take accomplishments review would I provide Salarius to I you new who are those the more to a on recent Before moment
Our by called interest cells. validated action oral in in a cancer a expression the as types analogy for cancer across with LSDX the A over plays clinic. drug, that cancer an code an in before differentiated LSDX several Seclidemstat genetic cancer-promoting mechanism development research gene LSDX of target numerous the appreciating that of and inhibitor carries novel, which inhibitors enzyme analogy widely for misreading its tablet LSDX. been of results inhibits expression, progression a good used reversible actually, in seclidemstat of enzyme is is has baking. decade, to gene area nucleus of cancers. dysregulated lead LSDX key from of an granted is LSDX a -- effects other the Targeting role activity and the causing compared dysregulated out the broad the I've the
in is cells development the correct the lead is quarter our of and follow you we dysregulation presented this ingredients and is the designed the it expression quantities. genetic ingredients the result the the in living to context All can the second amounts, cake. misread, of precisely a gene they're are research If the right a recipe progression believe occurs code and of is essentially or mix recipe genetic this our during to recipe. correct affirms and incorrect When there,however, cancer. that capability. Seclidemstat in right Dysregulated misreading successful
a and represented market or the accomplishments hematologic you hear into opportunities. program; future by represented development other two-prong sarcoma research discuss large and and to our will As by describe expand blood cancer me recent our speed continuing our market strategy; our program we market plans,
in twice reported XXXX profile, quarter, escalation ASCO oncologists a the trials poster successful or refractory a daily Let's oral provides achieving in first profile X twice also exposure relapse activity. in seclidemstat drug sarcomas. with in with were but goals demonstrated Three these we tumors. In poster meeting, range key progression largest we ASCO the ASCO. time the also that These now administered to clinical data Oncology drug patients. advanced the milligrams Ewing from commonly as in manageable sessions Society intended patients solid sarcoma greater a and researchers. including reported observations types sarcomas recommended top-line sarcoma to second in activity SES levels dose tissue detailed of and tolerable than advanced and of daily. seclidemstat two sarcoma used XXX American not seclidemstat and that safety a seclidemstat further dose study their our dose presentation patients Clinical talk This dose results only and that with of patients pharmacokinetic revealed both above world's FET-rearranged that at gathering at quarter. discussion has showed tolerable, is the trials and session referred is about and in Phase drug activity annual patients treated of single-agent preclinical second supports cancer in FET-rearranged benchmark provided was dosing establishing which Ewing with levels soft Back three quarter, The
potential cell in have we TC treating have progression that have are clinical comes seclidemstat's we trials. this with important means the sarcomas, Ewing of we with a progression-free number equal progression preliminary when sarcoma subset This trial from of FET-rearranged trial. we survival -- excited is to the number it treating one that single-agent synergy a expanded investigate with patients And times patients that excited TC, Let moment is accepted a to with understand in trial treatment patients small now drug advanced well groups; drug activity, sarcoma. that with two where our patients to that we are greater perspective. when that not Ewing and time sarcoma than which equals one single-agent as believe one activity does Meaning demonstrated potential with sarcoma already researching patients plus sarcoma. expansion for treated our related seclidemstat we sarcoma This their number this Ewing patients which to indicates with two me FET-rearranged data, sarcoma for seclidemstat of with synergistic sarcoma with is with When one two. is line, drug FET-rearranged time to or have is soft I preclinical us the and one and for Ewing take a while endpoint in seclidemstat we Yes, one combination data sarcomas there progression these tripled single-agent In when and seclidemstat activity. patient are to patients put where to sarcomas can only patient Ewing as but we are activity and more very because are Ewing extend therapy. registration we we plus just Three consider seen with to excited demonstrated data tissue in drug a upon given liposarcoma are topotecan patients research, to than of with anticancer in this seclidemstat sarcoma about These we activity a the help tell cyclophosphamide combined appears are types of is patients, additional equally time to results a It about Based myxoid two. you third-line can TC in sarcomas. sarcomas. dose patients begin to three help from therapy tripled the and single-agent in FET-rearranged combined sarcoma. seclidemstat's types common there seclidemstat sarcoma, important patients as is mentioned, plus activity refractory about seclidemstat FET-rearranged four why seclidemstat to second- because
with target six discussed, their generally the target tumors. reduction previously lesions Remember, have we defined saw of patient's lesions with just treatment cycles size a As patient alone with XX% treated after Ewing are refractory seclidemstat. prospectively the seclidemstat sarcoma a dramatic measurable of largest in
are sarcoma and achieve begin therapy combined improve seclidemstat that at to now of potentially positive building and single-agent patient and understand this Salarius believe outcomes excited our TC attacking sarcoma on responses. now Again, we the can on synergistic you Ewing overall activity with have impact could we are will objective by effect program we about why So, we the patients.
a position each Chase patients and year of is And into Fox to the have trial enrolled I'm the three trial we patient to and Center that as recruiting sites progresses in Cancer now provide are sarcoma our the and label, given in clinical in we that already addition actively happy sarcoma as this report trial recent enrolling the later our updates site, the we nine trial XXXX. have trial sarcoma open With groups. patients of
for newest our earlier introducing indications by which is further exciting second- The anticancer clinical to fact cycle escalation and that As of which from investor synergistic growth. the it and safety, the please informing addressable seclidemstat proceed. just allowed seclidemstat trial I event AST the advanced of opinion expand strong clinical foundation during trial happy a KOL But pipeline. of and Officer, new believe I before clinical FET-rearranged important have we us which our escalation trial our event trial the and key Rosenblum, during a third-line the with recent times, development discuss trial, the to few was need that strong opportunities. solid potentially apart that seclidemstat our larger highlighted would also and properties three, is sarcoma additional therapy the the that in therapy discuss we data, Chief seclidemstat generated the that financial like as of In leader and enabling clinical and completed this or all trial treatment amplified opinion this pharmacokinetic I'm report sarcomas activities. inhibitors. planning announcement LSDX myxoid liposarcoma patient potential trials stages accomplishments, the second indications, from additional into as our leveraged to our has dose Mark leader two to seclidemstat ask dose our Further, short, other additional development target sarcoma is we we've as discussed sarcoma tumor unmet of data results as population mentioned, the also in or AST or key demonstrated provided set I combination Financial as Mark, direct, research two, high, Ewing to one, direct market for pinpoint the
